ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Chronic Obstructive Pulmonary Disorder (COPD) Market Research Report 2025
Published Date: September 2025
|
Report Code: QYRE-Auto-26D2937
Home | Market Reports | Health| Health Conditions| Respiratory Conditions
Global Chronic Obstructive Pulmonary Disorder COPD Market Insights and Forecast to 2028
BUY CHAPTERS

Global Chronic Obstructive Pulmonary Disorder (COPD) Market Research Report 2025

Code: QYRE-Auto-26D2937
Report
September 2025
Pages:82
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
GSK
Pfizer Inc
Merck
Novartis
Astrazeneca plc
Boehringer Ingelheim
Teva Pharmaceuticals
Ario Pharma
Roche
Ache
Almirall
Aquinox Pharmaceuticals
ASMACURE
Astellas Pharma

Chronic Obstructive Pulmonary Disorder (COPD) Market

The global market for Chronic Obstructive Pulmonary Disorder (COPD) was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Chronic Obstructive Pulmonary Disease (COPD) is a chronic respiratory condition characterized by persistent airflow limitation that makes it difficult to breathe. COPD encompasses a group of diseases, with the most common being emphysema and chronic bronchitis.
Emphysema involves the destruction of the air sacs in the lungs, while chronic bronchitis is marked by inflammation and narrowing of the airways. Symptoms include shortness of breath, chronic cough, excessive mucus production, wheezing, and tightness in the chest. COPD is often caused by long-term exposure to irritants, such as cigarette smoke, air pollution, and occupational dust or chemicals.
The condition is progressive and can significantly impact an individual"s quality of life. In advanced stages, COPD can result in severe respiratory complications and exacerbations, potentially leading to hospitalizations.
Treatment for COPD typically involves a combination of medication, pulmonary rehabilitation, oxygen therapy, and in severe cases, surgical intervention such as lung volume reduction surgery or lung transplantation. Quitting smoking, avoiding lung irritants, and getting vaccinations to prevent respiratory infections are also essential components of COPD management.
COPD is a major public health concern globally, as it can cause significant morbidity and mortality. Early diagnosis, proper management, and lifestyle modifications are critical for maintaining the respiratory function and improving the well-being of individuals living with COPD.
This report aims to provide a comprehensive presentation of the global market for Chronic Obstructive Pulmonary Disorder (COPD), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Obstructive Pulmonary Disorder (COPD).
The Chronic Obstructive Pulmonary Disorder (COPD) market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Chronic Obstructive Pulmonary Disorder (COPD) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chronic Obstructive Pulmonary Disorder (COPD) companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Chronic Obstructive Pulmonary Disorder (COPD) Market Report

Report Metric Details
Report Name Chronic Obstructive Pulmonary Disorder (COPD) Market
Segment by Type
  • Short-Acting Bronchodilators
  • Corticosteroids
  • Methylxanthines
  • Long-Acting Bronchodilators
  • Phosphodiesterase-4 Inhibitors
  • Others
Segment by Application
  • Hospital
  • Clinic
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company GSK, Pfizer, Merck, Novartis, AstraZeneca, Boehringer Ingelheim, Teva Pharmaceuticals, Ario Pharma, Roche, Ache, Almirall, Aquinox Pharmaceuticals, Asmacure, Astellas Pharma
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Chronic Obstructive Pulmonary Disorder (COPD) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Chronic Obstructive Pulmonary Disorder (COPD) Market report?

Ans: The main players in the Chronic Obstructive Pulmonary Disorder (COPD) Market are GSK, Pfizer, Merck, Novartis, AstraZeneca, Boehringer Ingelheim, Teva Pharmaceuticals, Ario Pharma, Roche, Ache, Almirall, Aquinox Pharmaceuticals, Asmacure, Astellas Pharma

What are the Application segmentation covered in the Chronic Obstructive Pulmonary Disorder (COPD) Market report?

Ans: The Applications covered in the Chronic Obstructive Pulmonary Disorder (COPD) Market report are Hospital, Clinic

What are the Type segmentation covered in the Chronic Obstructive Pulmonary Disorder (COPD) Market report?

Ans: The Types covered in the Chronic Obstructive Pulmonary Disorder (COPD) Market report are Short-Acting Bronchodilators, Corticosteroids, Methylxanthines, Long-Acting Bronchodilators, Phosphodiesterase-4 Inhibitors, Others

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Short-Acting Bronchodilators
1.2.3 Corticosteroids
1.2.4 Methylxanthines
1.2.5 Long-Acting Bronchodilators
1.2.6 Phosphodiesterase-4 Inhibitors
1.2.7 Others
1.3 Market by Application
1.3.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Perspective (2020-2031)
2.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Growth Trends by Region
2.2.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Chronic Obstructive Pulmonary Disorder (COPD) Historic Market Size by Region (2020-2025)
2.2.3 Chronic Obstructive Pulmonary Disorder (COPD) Forecasted Market Size by Region (2026-2031)
2.3 Chronic Obstructive Pulmonary Disorder (COPD) Market Dynamics
2.3.1 Chronic Obstructive Pulmonary Disorder (COPD) Industry Trends
2.3.2 Chronic Obstructive Pulmonary Disorder (COPD) Market Drivers
2.3.3 Chronic Obstructive Pulmonary Disorder (COPD) Market Challenges
2.3.4 Chronic Obstructive Pulmonary Disorder (COPD) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Chronic Obstructive Pulmonary Disorder (COPD) Players by Revenue
3.1.1 Global Top Chronic Obstructive Pulmonary Disorder (COPD) Players by Revenue (2020-2025)
3.1.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Players (2020-2025)
3.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Chronic Obstructive Pulmonary Disorder (COPD) Revenue
3.4 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Concentration Ratio
3.4.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chronic Obstructive Pulmonary Disorder (COPD) Revenue in 2024
3.5 Global Key Players of Chronic Obstructive Pulmonary Disorder (COPD) Head office and Area Served
3.6 Global Key Players of Chronic Obstructive Pulmonary Disorder (COPD), Product and Application
3.7 Global Key Players of Chronic Obstructive Pulmonary Disorder (COPD), Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Chronic Obstructive Pulmonary Disorder (COPD) Breakdown Data by Type
4.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Historic Market Size by Type (2020-2025)
4.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Forecasted Market Size by Type (2026-2031)
5 Chronic Obstructive Pulmonary Disorder (COPD) Breakdown Data by Application
5.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Historic Market Size by Application (2020-2025)
5.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2020-2031)
6.2 North America Chronic Obstructive Pulmonary Disorder (COPD) Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2020-2025)
6.4 North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2020-2031)
7.2 Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2020-2025)
7.4 Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2020-2031)
8.2 Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region (2020-2025)
8.4 Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2020-2031)
9.2 Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2020-2025)
9.4 Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2020-2031)
10.2 Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2020-2025)
10.4 Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GSK
11.1.1 GSK Company Details
11.1.2 GSK Business Overview
11.1.3 GSK Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.1.4 GSK Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2020-2025)
11.1.5 GSK Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Details
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.2.4 Pfizer Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2020-2025)
11.2.5 Pfizer Recent Development
11.3 Merck
11.3.1 Merck Company Details
11.3.2 Merck Business Overview
11.3.3 Merck Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.3.4 Merck Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2020-2025)
11.3.5 Merck Recent Development
11.4 Novartis
11.4.1 Novartis Company Details
11.4.2 Novartis Business Overview
11.4.3 Novartis Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.4.4 Novartis Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2020-2025)
11.4.5 Novartis Recent Development
11.5 AstraZeneca
11.5.1 AstraZeneca Company Details
11.5.2 AstraZeneca Business Overview
11.5.3 AstraZeneca Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.5.4 AstraZeneca Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2020-2025)
11.5.5 AstraZeneca Recent Development
11.6 Boehringer Ingelheim
11.6.1 Boehringer Ingelheim Company Details
11.6.2 Boehringer Ingelheim Business Overview
11.6.3 Boehringer Ingelheim Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.6.4 Boehringer Ingelheim Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2020-2025)
11.6.5 Boehringer Ingelheim Recent Development
11.7 Teva Pharmaceuticals
11.7.1 Teva Pharmaceuticals Company Details
11.7.2 Teva Pharmaceuticals Business Overview
11.7.3 Teva Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.7.4 Teva Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2020-2025)
11.7.5 Teva Pharmaceuticals Recent Development
11.8 Ario Pharma
11.8.1 Ario Pharma Company Details
11.8.2 Ario Pharma Business Overview
11.8.3 Ario Pharma Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.8.4 Ario Pharma Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2020-2025)
11.8.5 Ario Pharma Recent Development
11.9 Roche
11.9.1 Roche Company Details
11.9.2 Roche Business Overview
11.9.3 Roche Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.9.4 Roche Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2020-2025)
11.9.5 Roche Recent Development
11.10 Ache
11.10.1 Ache Company Details
11.10.2 Ache Business Overview
11.10.3 Ache Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.10.4 Ache Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2020-2025)
11.10.5 Ache Recent Development
11.11 Almirall
11.11.1 Almirall Company Details
11.11.2 Almirall Business Overview
11.11.3 Almirall Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.11.4 Almirall Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2020-2025)
11.11.5 Almirall Recent Development
11.12 Aquinox Pharmaceuticals
11.12.1 Aquinox Pharmaceuticals Company Details
11.12.2 Aquinox Pharmaceuticals Business Overview
11.12.3 Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.12.4 Aquinox Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2020-2025)
11.12.5 Aquinox Pharmaceuticals Recent Development
11.13 Asmacure
11.13.1 Asmacure Company Details
11.13.2 Asmacure Business Overview
11.13.3 Asmacure Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.13.4 Asmacure Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2020-2025)
11.13.5 Asmacure Recent Development
11.14 Astellas Pharma
11.14.1 Astellas Pharma Company Details
11.14.2 Astellas Pharma Business Overview
11.14.3 Astellas Pharma Chronic Obstructive Pulmonary Disorder (COPD) Introduction
11.14.4 Astellas Pharma Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2020-2025)
11.14.5 Astellas Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
GSK
Pfizer Inc
Merck
Novartis
Astrazeneca plc
Boehringer Ingelheim
Teva Pharmaceuticals
Ario Pharma
Roche
Ache
Almirall
Aquinox Pharmaceuticals
ASMACURE
Astellas Pharma
List of Tables
 Table 1. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Short-Acting Bronchodilators
 Table 3. Key Players of Corticosteroids
 Table 4. Key Players of Methylxanthines
 Table 5. Key Players of Long-Acting Bronchodilators
 Table 6. Key Players of Phosphodiesterase-4 Inhibitors
 Table 7. Key Players of Others
 Table 8. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 9. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 10. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region (2020-2025) & (US$ Million)
 Table 11. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Region (2020-2025)
 Table 12. Global Chronic Obstructive Pulmonary Disorder (COPD) Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 13. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Region (2026-2031)
 Table 14. Chronic Obstructive Pulmonary Disorder (COPD) Market Trends
 Table 15. Chronic Obstructive Pulmonary Disorder (COPD) Market Drivers
 Table 16. Chronic Obstructive Pulmonary Disorder (COPD) Market Challenges
 Table 17. Chronic Obstructive Pulmonary Disorder (COPD) Market Restraints
 Table 18. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Players (2020-2025) & (US$ Million)
 Table 19. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Players (2020-2025)
 Table 20. Global Top Chronic Obstructive Pulmonary Disorder (COPD) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Obstructive Pulmonary Disorder (COPD) as of 2024)
 Table 21. Ranking of Global Top Chronic Obstructive Pulmonary Disorder (COPD) Companies by Revenue (US$ Million) in 2024
 Table 22. Global 5 Largest Players Market Share by Chronic Obstructive Pulmonary Disorder (COPD) Revenue (CR5 and HHI) & (2020-2025)
 Table 23. Global Key Players of Chronic Obstructive Pulmonary Disorder (COPD), Headquarters and Area Served
 Table 24. Global Key Players of Chronic Obstructive Pulmonary Disorder (COPD), Product and Application
 Table 25. Global Key Players of Chronic Obstructive Pulmonary Disorder (COPD), Date of Enter into This Industry
 Table 26. Mergers & Acquisitions, Expansion Plans
 Table 27. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Type (2020-2025) & (US$ Million)
 Table 28. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Type (2020-2025)
 Table 29. Global Chronic Obstructive Pulmonary Disorder (COPD) Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 30. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Type (2026-2031)
 Table 31. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Application (2020-2025) & (US$ Million)
 Table 32. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Application (2020-2025)
 Table 33. Global Chronic Obstructive Pulmonary Disorder (COPD) Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 34. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Application (2026-2031)
 Table 35. North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 36. North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2020-2025) & (US$ Million)
 Table 37. North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2026-2031) & (US$ Million)
 Table 38. Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 39. Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2020-2025) & (US$ Million)
 Table 40. Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2026-2031) & (US$ Million)
 Table 41. Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 42. Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region (2020-2025) & (US$ Million)
 Table 43. Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region (2026-2031) & (US$ Million)
 Table 44. Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 45. Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2020-2025) & (US$ Million)
 Table 46. Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2026-2031) & (US$ Million)
 Table 47. Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 48. Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2020-2025) & (US$ Million)
 Table 49. Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2026-2031) & (US$ Million)
 Table 50. GSK Company Details
 Table 51. GSK Business Overview
 Table 52. GSK Chronic Obstructive Pulmonary Disorder (COPD) Product
 Table 53. GSK Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2020-2025) & (US$ Million)
 Table 54. GSK Recent Development
 Table 55. Pfizer Company Details
 Table 56. Pfizer Business Overview
 Table 57. Pfizer Chronic Obstructive Pulmonary Disorder (COPD) Product
 Table 58. Pfizer Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2020-2025) & (US$ Million)
 Table 59. Pfizer Recent Development
 Table 60. Merck Company Details
 Table 61. Merck Business Overview
 Table 62. Merck Chronic Obstructive Pulmonary Disorder (COPD) Product
 Table 63. Merck Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2020-2025) & (US$ Million)
 Table 64. Merck Recent Development
 Table 65. Novartis Company Details
 Table 66. Novartis Business Overview
 Table 67. Novartis Chronic Obstructive Pulmonary Disorder (COPD) Product
 Table 68. Novartis Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2020-2025) & (US$ Million)
 Table 69. Novartis Recent Development
 Table 70. AstraZeneca Company Details
 Table 71. AstraZeneca Business Overview
 Table 72. AstraZeneca Chronic Obstructive Pulmonary Disorder (COPD) Product
 Table 73. AstraZeneca Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2020-2025) & (US$ Million)
 Table 74. AstraZeneca Recent Development
 Table 75. Boehringer Ingelheim Company Details
 Table 76. Boehringer Ingelheim Business Overview
 Table 77. Boehringer Ingelheim Chronic Obstructive Pulmonary Disorder (COPD) Product
 Table 78. Boehringer Ingelheim Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2020-2025) & (US$ Million)
 Table 79. Boehringer Ingelheim Recent Development
 Table 80. Teva Pharmaceuticals Company Details
 Table 81. Teva Pharmaceuticals Business Overview
 Table 82. Teva Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Product
 Table 83. Teva Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2020-2025) & (US$ Million)
 Table 84. Teva Pharmaceuticals Recent Development
 Table 85. Ario Pharma Company Details
 Table 86. Ario Pharma Business Overview
 Table 87. Ario Pharma Chronic Obstructive Pulmonary Disorder (COPD) Product
 Table 88. Ario Pharma Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2020-2025) & (US$ Million)
 Table 89. Ario Pharma Recent Development
 Table 90. Roche Company Details
 Table 91. Roche Business Overview
 Table 92. Roche Chronic Obstructive Pulmonary Disorder (COPD) Product
 Table 93. Roche Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2020-2025) & (US$ Million)
 Table 94. Roche Recent Development
 Table 95. Ache Company Details
 Table 96. Ache Business Overview
 Table 97. Ache Chronic Obstructive Pulmonary Disorder (COPD) Product
 Table 98. Ache Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2020-2025) & (US$ Million)
 Table 99. Ache Recent Development
 Table 100. Almirall Company Details
 Table 101. Almirall Business Overview
 Table 102. Almirall Chronic Obstructive Pulmonary Disorder (COPD) Product
 Table 103. Almirall Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2020-2025) & (US$ Million)
 Table 104. Almirall Recent Development
 Table 105. Aquinox Pharmaceuticals Company Details
 Table 106. Aquinox Pharmaceuticals Business Overview
 Table 107. Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Product
 Table 108. Aquinox Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2020-2025) & (US$ Million)
 Table 109. Aquinox Pharmaceuticals Recent Development
 Table 110. Asmacure Company Details
 Table 111. Asmacure Business Overview
 Table 112. Asmacure Chronic Obstructive Pulmonary Disorder (COPD) Product
 Table 113. Asmacure Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2020-2025) & (US$ Million)
 Table 114. Asmacure Recent Development
 Table 115. Astellas Pharma Company Details
 Table 116. Astellas Pharma Business Overview
 Table 117. Astellas Pharma Chronic Obstructive Pulmonary Disorder (COPD) Product
 Table 118. Astellas Pharma Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2020-2025) & (US$ Million)
 Table 119. Astellas Pharma Recent Development
 Table 120. Research Programs/Design for This Report
 Table 121. Key Data Information from Secondary Sources
 Table 122. Key Data Information from Primary Sources
 Table 123. Authors List of This Report


List of Figures
 Figure 1. Chronic Obstructive Pulmonary Disorder (COPD) Picture
 Figure 2. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Type: 2024 VS 2031
 Figure 4. Short-Acting Bronchodilators Features
 Figure 5. Corticosteroids Features
 Figure 6. Methylxanthines Features
 Figure 7. Long-Acting Bronchodilators Features
 Figure 8. Phosphodiesterase-4 Inhibitors Features
 Figure 9. Others Features
 Figure 10. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Application (2020-2031) & (US$ Million)
 Figure 11. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Application: 2024 VS 2031
 Figure 12. Hospital Case Studies
 Figure 13. Clinic Case Studies
 Figure 14. Chronic Obstructive Pulmonary Disorder (COPD) Report Years Considered
 Figure 15. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 16. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 17. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Region: 2024 VS 2031
 Figure 18. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Players in 2024
 Figure 19. Global Top Chronic Obstructive Pulmonary Disorder (COPD) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Obstructive Pulmonary Disorder (COPD) as of 2024)
 Figure 20. The Top 10 and 5 Players Market Share by Chronic Obstructive Pulmonary Disorder (COPD) Revenue in 2024
 Figure 21. North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. North America Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Country (2020-2031)
 Figure 23. United States Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Canada Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Country (2020-2031)
 Figure 27. Germany Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. France Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. U.K. Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Italy Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Russia Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Nordic Countries Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Region (2020-2031)
 Figure 35. China Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Japan Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. South Korea Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Southeast Asia Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. India Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Australia Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Country (2020-2031)
 Figure 43. Mexico Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Brazil Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Country (2020-2031)
 Figure 47. Turkey Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. Saudi Arabia Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 49. UAE Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 50. GSK Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2020-2025)
 Figure 51. Pfizer Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2020-2025)
 Figure 52. Merck Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2020-2025)
 Figure 53. Novartis Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2020-2025)
 Figure 54. AstraZeneca Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2020-2025)
 Figure 55. Boehringer Ingelheim Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2020-2025)
 Figure 56. Teva Pharmaceuticals Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2020-2025)
 Figure 57. Ario Pharma Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2020-2025)
 Figure 58. Roche Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2020-2025)
 Figure 59. Ache Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2020-2025)
 Figure 60. Almirall Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2020-2025)
 Figure 61. Aquinox Pharmaceuticals Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2020-2025)
 Figure 62. Asmacure Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2020-2025)
 Figure 63. Astellas Pharma Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2020-2025)
 Figure 64. Bottom-up and Top-down Approaches for This Report
 Figure 65. Data Triangulation
 Figure 66. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIS Group of Schools

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Inhaled Treatment for Asthma and COPD Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-19Y19888
Tue Sep 09 00:00:00 UTC 2025

Add to Cart

Global Oxygen Inhaler Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-11D3386
Tue Sep 09 00:00:00 UTC 2025

Add to Cart

Global Chronic Obstructive Pulmonary Disorder (COPD) Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-26D2937
Mon Sep 08 00:00:00 UTC 2025

Add to Cart

Global Bronchiectasis Treatment Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-18E6080
Mon Sep 08 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions